|
1
|
Ouyang RC, Kenwright DN, Nacey JN and
Delahunt B: The presence of atypical small acinar proliferation in
prostate needle biopsy is predictive of carcinoma on subsequent
biopsy. BJU Int. 87:70–74. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodge KK, McNeal JE, Terris MK and Stamey
TA: Random systematic versus directed ultrasound guided transrectal
core biopsies of the prostate. J Urol. 142:71–75. 1989.PubMed/NCBI
|
|
3
|
Rabbani F, Stroumbakis N, Kava BR, Cookson
MS and Fair WR: Incidence and clinical significance of
false-negative sextant prostate biopsies. J Urol. 159:1247–1250.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Norberg M, Egevad L, Holmberg L, Sparèn P,
Norlèn BJ and Busch C: The sextant protocol for ultrasound-guided
core biopsies of the prostate underestimates the presence of
cancer. Urology. 50:562–566. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pepe P and Aragona F: Prostate needle
biopsy: 12 vs. 18 cores - is it necessary? Urol Int. 74:19–22.
2005.PubMed/NCBI
|
|
6
|
Ficarra V, Novella G, Novara G, Galfano A,
Pea M, Martignoni G and Artibani W: The potential impact of
prostate volume in the planning of optimal number of cores in the
systematic transperineal prostate biopsy. Eur Urol. 48:932–937.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schröder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, et al: Screening and prostate-cancer mortality in a
randomized European study. N Engl J Med. 360:1320–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andriole GL, Crawford ED, Grubb RL III,
Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding
DJ, et al: Mortality results from a randomized prostate-cancer
screening trial. N Engl J Med. 360:1310–1319. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abdollah F, Novara G, Briganti A, Scattoni
V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V,
et al: Transrectal versus transperineal saturation rebiopsy of the
prostate: Is there a difference in cancer detection rate? Urology.
77:921–925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Merrick GS, Gutman S, Andreini H,
Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen
Z, Butler W and Wallner K: Prostate cancer distribution in patients
diagnosed by transperineal template-guided saturation biopsy. Eur
Urol. 52:715–723. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borboroglu PG, Corner SW, Riffenburgh RH
and Amling CL: Extensive repeat transrectal ultrasound-guided
prostate biopsy in patient with previous benign sextant biopsies. J
Urol. 163:158–162. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stewart CS, Leibovich BC, Weaver AL and
Lieber MM: Prostate cancer diagnosis using a saturation needle
biopsy technique after previous negative sextant biopsies. J Urol.
166:86–92. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morote J, Lopez M, Encabo G and de Torres
IM: Effect of inflammation and benign prostatic enlargement on
total and percent free serum prostatic specific antigen. Eur Urol.
37:537–540. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kato T, Suzuki H, Komiya A, Imamoto T,
Naya Y, Tobe T and Ichikawa T: Clinical significance of urinary
white blood cell count and serum C-reactive protein level for
detection of non-palpable prostate cancer. Int J Urol. 13:915–919.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hellmann F, Verdi M, Schlemper BR Jr and
Caponi S: 50th anniversary of the Declaration of Helsinki: The
double standard was introduced. Arch Med Res. 45:600–601. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL: ISUP Grading Committee: The 2005 International Society
of Urological Pathology (ISUP) Consensus Conference on Gleason
Grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krieger JN, Nyberg L Jr and Nickel JC: NIH
consensus definition and classification of prostatitis. JAMA.
282:236–237. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tosoian JJ, Trock BJ, Landis P, Feng Z,
Epstein JI, Partin AW, Walsh PC and Carter HB: Active surveillance
program for prostate cancer: An update of the Johns Hopkins
experience. J Clin Oncol. 29:2185–2190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oesterling JE: Prostate specific antigen:
A critical assessment of the most useful tumor marker for
adenocarcinoma of the prostate. J Urol. 145:907–923.
1991.PubMed/NCBI
|
|
20
|
Kawakami S, Kihara K, Fujii Y, Masuda H,
Kobayashi T and Kageyama Y: Transrectal ultrasound-guided
transperineal 14-core systematic biopsy detects apico-anterior
cancer foci of T1c prostate cancer. Int J Urol. 11:613–618. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shannon BA, McNeal JE and Cohen RJ:
Transition zone carcinoma of the prostate gland: A common indolent
tumor type that occasionally manifests aggressive behaviour.
Pathology. 35:467–471. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zaytoun OM, Moussa AS, Gao T, Fareed K and
Jones JS: Office-based transrectal saturation biopsy improves
prostate cancer detection compared to extended biopsy in the repeat
biopsy population. J Urol. 186:850–854. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bastian PJ, Mangold LA, Epstein JI and
Partin AW: Characteristics of insignificant clinical T1c prostate
tumors. A contemporary analysis. Cancer. 101:2001–2005. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Epstein JI, Sanderson H, Carter HB and
Scharfstein DO: Utility of saturation biopsy to predict
insignificant cancer at radical prostatectomy. Urology. 66:356–360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gann PH, Fought A, Deaton R, Catalona WJ
and Vonesh E: Risk factors for prostate cancer detection after a
negative biopsy: A novel multivariable longitudinal approach. J
Clin Oncol. 28:1714–1720. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Djavan B, Fong YK, Ravery V, Remzi M,
Horninger W, Susani M, Kreuzer S, Boccon-Gibod L, Bartsch G and
Marberger M: Are repeat biopsies required in men with PSA levels
< or =4 ng/ml? A multi-institutional prospective European study.
Eur Urol. 47:38–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brawer MK: The influence of prostate
volume on prostate cancer detection. Eur Urol Suppl. 1:35–39. 2002.
View Article : Google Scholar
|
|
28
|
Campos-Fernandes JL, Bastien L, Nicolaiew
N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D,
Hoznek A, et al: Prostate cancer detection rate in patients with
repeated extended 21-sample needle biopsy. Eur Urol. 55:600–606.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sajadi KP, Kim T, Terris MK, Brown JA and
Lewis RW: High yield of saturation prostate biopsy for patients
with previous negative biopsies and small prostates. Urology.
70:691–695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oderda M and Gontero P: High-grade
prostatic intraepithelial neoplasia and atypical small acinar
proliferation: Is repeat biopsy still necessary? BJU Int.
104:1554–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Inahara M, Suzuki H, Nakamachi H, Kamiya
N, Shimbo M, Komiya A, Ueda T, Ichikawa T, Akakura K and Ito H:
Clinical evaluation of transrectal power doppler imaging in the
detection of prostate cancer. Int Urol Nephrol. 36:175–180. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chan TY and Epstein JI: Follow-up of
atypical prostate needle biopsies suspicious for cancer. Urology.
53:351–355. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heidenreich A, Aus G, Bolla M, Joniau S,
Matveev VB, Schmid HP and Zattoni F: European Association of
Urology: EAU guidelines on prostate cancer. Eur Urol. 53:68–80.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stamey TA, Yang N, Hay AR, McNeal JE,
Freiha FS and Redwine E: Prostate-specific antigen as a serum
marker for adenocarcinoma of the prostate. N Engl J Med.
317:909–916. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yaman O, Göğüş C, Tulunay O, Tokatli Z and
Ozden E: Increased prostate-specific antigen in subclinical
prostatitis: The role of aggressiveness and extension of
inflammation. Urol Int. 71:160–164. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schatteman PH, Hoekx L, Wyndaele JJ,
Jeuris W and Van Marck E: Inflammation in prostate biopsies of men
without prostatic malignancy or clinical prostatitis: Correlation
with total serum PSA and PSA density. Eur Urol. 37:404–412. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kandirali E, Boran C, Serin E, Semercioz A
and Metin A: Association of extent and aggressiveness of
inflammation with serum PSA levels and PSA density in asymptomatic
patients. Urology. 70:743–747. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Terakawa T, Miyake H, Kanomata N, Kumano
M, Takenaka A and Fujisawao M: Inverse association between
histologic inflammation in needle biopsy specimens and prostate
cancer in men with serum PSA of 10–50 ng/ml. Urology. 72:1194–1197.
2008. View Article : Google Scholar : PubMed/NCBI
|
